Senate Bill Proposes AI Tech Expansion and Reimbursement in Healthcare

A bipartisan Senate bill introduced this week proposes expanding the range of AI technologies approved for clinical use and creating reimbursement pathways for AI-enabled healthcare services, signaling a major federal policy shift to mainstream AI in medicine HealthTech News Medical Policy Journal.

The bill, unveiled on June 10, 2024, by Senators Amy Klobuchar (D-MN) and Bill Cassidy (R-LA), directs the Department of Health and Human Services (HHS) to broaden the list of AI applications eligible for use in diagnostics, treatment planning, and patient monitoring. It also mandates the Centers for Medicare & Medicaid Services (CMS) to develop reimbursement models for AI-driven services, making it financially viable for providers to integrate AI tools into clinical workflows HealthTech News. The legislation targets hospitals, health systems, and providers participating in federal healthcare programs, with the goal of accelerating AI adoption across the sector Medical Policy Journal.

The move comes as healthcare organizations face mounting pressure to improve outcomes and reduce costs, while navigating regulatory frameworks like HIPAA and the FDA’s Software as a Medical Device (SaMD) guidelines. By explicitly linking reimbursement to AI-enabled services, the bill addresses a key barrier to enterprise AI deployment: lack of payment incentives. It also signals Congressional intent to align federal policy with the EU AI Act’s approach to regulated AI in healthcare, and to support NIST AI Risk Management Framework (RMF) adoption for safe, effective AI integration NIST AI RMF.

If enacted, the bill would require CTOs and CISOs at health systems to rapidly assess their AI portfolios for compliance with new federal standards, and to prepare for CMS audits of AI-enabled billing. Compliance Officers should anticipate new HHS guidance on data privacy, algorithmic transparency, and clinical validation for reimbursable AI tools. Over the next 30-90 days, enterprise leaders should monitor the bill’s progress, evaluate vendor AI solutions for regulatory readiness, and update risk management protocols to align with anticipated federal requirements.

What This Means for Enterprise AI

Healthcare CTOs should immediately review their AI deployment roadmaps, prioritizing solutions that align with the bill’s expanded use cases—especially in diagnostics, treatment planning, and patient monitoring. Existing and planned AI tools must be evaluated for compliance with HIPAA privacy and security rules, as well as FDA SaMD requirements, to ensure eligibility for future reimbursement FDA SaMD. CISOs must prepare for increased scrutiny of AI system security and auditability, as CMS reimbursement will likely require robust documentation of AI decision-making and data handling practices NIST AI RMF. Compliance Officers should anticipate new HHS guidance on algorithmic transparency and clinical validation, and begin mapping internal controls to expected federal standards.

For regulated enterprises, the bill’s reimbursement provisions create a financial incentive to accelerate AI adoption, but also raise the bar for regulatory compliance and risk management. Health systems should initiate cross-functional reviews of their AI governance frameworks, update vendor due diligence processes, and engage legal counsel to interpret evolving federal requirements. Early action will position organizations to capitalize on new reimbursement opportunities while mitigating regulatory and operational risks.